All reviews of published articles are made public. This includes manuscript files, peer review comments, author rebuttals and revised materials. Note: This was optional for articles submitted before 13 February 2023.
Peer reviewers are encouraged (but not required) to provide their names to the authors when submitting their peer review. If they agree to provide their name, then their personal profile page will reflect a public acknowledgment that they performed a review (even if the article is rejected). If the article is accepted, then reviewers who provided their name will be associated with the article itself.
As the reviewers are satisfied with the current version and I also find the manuscript ready for publication, I would like to congratulate you on a job well done.
Thank you for your efforts, and I wish your work great visibility and impact.
[# PeerJ Staff Note - this decision was reviewed and approved by Sonia Oliveira, a PeerJ Section Editor covering this Section #]
no comment
no comment
no comment
Authors had made sufficient revisions to address my comments, and I recommend accepting the manuscript.
The authors have addressed my concerns to my satisfaction.
The review is comprehensive.
The article is comprehensive.
The manuscript provides a thorough review of c-Myc’s role in psoriasis pathogenesis but would benefit from a deeper discussion on the therapeutic implications of targeting c-Myc, the direct (if possible at all) and indirect targeting (please mention several potential targets and novel achievements). Expanding on current psoriasis treatments, their limitations, and potential c-Myc-targeted strategies (such as inhibitors or gene therapy) could increase the novelty and translational value of the review. Additionally, the authors should clarify the coexisting factors that interact with c-Myc in cell proliferation and apoptosis, and address the role of c-Myc in keratinization and inflammatory responses in keratinocytes. This would strengthen the manuscript and make it more clinically relevant.
**PeerJ Staff Note:** Please ensure that all review, editorial, and staff comments are addressed in a response letter and that any edits or clarifications mentioned in the letter are also inserted into the revised manuscript where appropriate.
The manuscript provides a clear and well-structured overview of the biological functions of c-Myc and its role in psoriasis pathogenesis. The language is professional and unambiguous, and the review is supported by relevant literature. However, the novelty of the article is somewhat lacking. While the authors comprehensively describe the biological functions of c-Myc and its involvement in psoriasis, the discussion does not sufficiently extend to the therapeutic implications of targeting c-Myc in psoriasis treatment.
To enhance the impact of the review, I suggest the authors expand their discussion on current therapeutic limitations for psoriasis and emphasize the potential of c-Myc as a therapeutic target. Specifically, a comparative analysis of existing psoriasis treatments and their shortcomings (such as biologics, small-molecule inhibitors, and systemic therapies) could help establish the clinical relevance of c-Myc inhibition. Furthermore, discussing potential c-Myc-targeted strategies, including inhibitors, gene therapy, or metabolic interventions, would improve the manuscript’s novelty and provide a more translational perspective.
Addressing these points would make the review more valuable to both researchers and clinicians, reinforcing the potential role of c-Myc in future therapeutic approaches for psoriasis.
As this is a review article, the traditional study design criteria do not apply.
The references cited in the manuscript are generally relevant and provide strong support for the biological functions of c-Myc and its role in psoriasis. However, most of the references focus on molecular and cellular mechanisms rather than clinical dermatology. Given that psoriasis is a chronic immune-mediated skin disease with a significant clinical burden, it is crucial to integrate more discussion on clinical aspects to enhance the translational value of the review.
None
The manuscript provides a comprehensive review of the role of the transcription factor c-Myc in the pathogenesis of psoriasis. The authors offer an in-depth analysis of c-Myc’s function in cell proliferation, apoptosis, metabolic reprogramming, and related processes. However, several concerns should be addressed:
The authors state, "The genes co-expressed with c-Myc and the coexisting factors determine the fate of cells. If the 213 coexisting factors stimulate c-Myc to promote cell proliferation, it is manifested as cell 214 proliferation" (lines 212–215). This statement is somewhat superficial. The authors should provide more detailed information regarding the coexisting factors. Specifically, they should identify which factors interact with c-Myc to drive cell proliferation and, similarly, which factors contribute to apoptosis.
Psoriasis is a skin disease also characterized by aberrant keratinization. It would be valuable to discuss the role of c-Myc in the keratinization process of keratinocytes (KCs) and how its dysregulation may contribute to disease pathology.
Additionally, exploring the role of c-Myc in the inflammatory response within KCs would further enhance the manuscript. Including this aspect would provide a more comprehensive understanding of c-Myc’s involvement in psoriasis.
no comment
no comment
All text and materials provided via this peer-review history page are made available under a Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.